BioTissue Technologies AG
BioTissue AG english
Q1 2001, New Sales and Earnings Targets for 2002
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
– Boosted Sales in Q1 2002
– New Sales and Earnings Targets for 2002
– Strategic Focus on Lucrative Market Segments
Freiburg, May 6, 2002 – BioTissue Technologies AG (SIN 618061) has boosted sales
in Q1 2002 to Euro 0.33 million, as against Euro 0.09 million in the year-
before period. The loss before interest and taxes for the first quarter came to
Euro 1.55 million compared to a loss of Euro 1.18 million in Q1 2001.
At the same time as announcing the figures for the first three months, BioTissue
Technologies is setting new sales and earnings targets for financial 2002.
Given the ongoing deterioration in overall conditions in the healthcare sector,
the Company expects that its innovative products will take longer penetrating
the market. Specifically the financing opportunities through the statutory
health insurance companies are hardest hit by such constraints.
In business 2002, sales are now scheduled to rise on the figure of Euro 1.13
million by some 150 %. We had hitherto assumed an increase of some 400 percent.
By means of strict cost management we intend to lower expenses. Among other
things, the current payroll will only be expanded to a limited extent and human
resource development aligned to growth and the changed expectations. Compared
with the prior budgets, personnel expenses will be 16 percent down in 2002 and
36 percent lower in 2003.
In this way, we intend to reduce the loss before interest and taxes for
financial 2002 by 10 percent to Euro 5.2 million as against a loss of Euro 5.8
million last year. Our original budgets envisaged the loss being pruned by about
20 percent.
Owing to this revised targets, we now do not expect operative business to start
turning a profit until 2004, whereas we had originally targeted 2003 for the
break even. As a consequence, for the second half of 2003 we will require
further cash resources of some Euro 1.2 million and are assessing whether to
take these up through the authorized capital. As at March 31, 2002 BioTissue
Technologies AG still possessed cash and cash equivalents of Euro 6.78 million.
The equity ratio ran at about 78 percent.
BioTissue Technologies AG, Martin Braendle, Investor Relations Manager
Phone: +49-761-7676110, martin.braendle@biotissue-tec.com
end of ad-hoc-announcement (c)DGAP 06.05.2002
Issuer’s information/explanatory remarks concerning this ad-hoc-announcement:
The Company’s strategic focus will in the future concentrate more strongly on
the large and especially lucrative markets in dental medicine, jaw surgery,
emergency surgery and orthopedics. With our autologous bone replacement BioSeed-
Oral Bone and BioSeed-C, our 3D cartilage replacement, two very promising
products are already positioned in these market segments. Both BioSeed-Oral Bone
and BioSeed-C have appreciable product and application advantages over
competing products and are protected by patents.
BioTissue Technologies AG, Martin Braendle, Investor Relations Manager
Phone: +49-761-7676110, martin.braendle@biotissue-tec.com
——————————————————————————–
WKN: 618061; ISIN: DE0006180615; Index:
Listed: Neuer Markt in Frankfurt;
Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und
Stuttgart
060824 Mai 02
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden